About Incyte
Incyte is a biopharmaceutical company focused on developing treatments across Hematology, Oncology, and Inflammation and Autoimmunity. Its work centers on advancing medicines intended to improve patients’ lives, and its discovery approach is built around a portfolio of scientifically differentiated compounds. Simple enough.
Founded in Wilmington, Delaware, Incyte has grown into a global organization with operations in 13 countries across North America, Europe, and Asia, while the company employs more than 2,800 people and is headquartered in Wilmington, Delaware, United States. A wide footprint.
Incyte was founded in 1991. The company serves patients through its development pipeline and treatment portfolio, and it has been recognized as a Top Employer by Science magazine for eight consecutive years, as well as by Newsweek and the Best Practice Institute in workplace rankings.
Need to reach the Incyte team directly? Find verified work emails for every employee with Snov.io
Insights
Updated 31 Aug 2026Incyte is getting renewed attention from investors as a healthcare name outside the AI capex trade, and Josh Brown of Ritholtz Wealth Management highlighted it as one of his “Best Stocks in the Market.” The setup looks supportive. Institutional ownership also points in a positive direction, since Wellington Management increased its stake and Manulife initiated a new position in the second quarter.
At a strategic level, the company is still focused on its oncology and immunology pipeline. Recent interest has centered on its KRAS G12D inhibitor 734 and upcoming ESMO data in pancreatic ductal adenocarcinoma, while coverage of oral JAK inhibitors in hidradenitis suppurativa and alopecia areata shows that the broader JAK space remains an important competitive and therapeutic backdrop for Incyte.
Market tone around Incyte is constructive. Recent commentary says attention has returned after a strong share-price run, and healthcare-stock rotation away from AI and data-center themes may be helping sentiment; no funding or earnings updates were provided in the supplied sources.
Frequently asked questions
Incyte is headquartered in Wilmington, Delaware, United States.
Incyte has 1001-5000 employees according to its company profile.
Incyte operates in the Pharmaceuticals sector. Public valuation figures are not always disclosed for private companies.